17 news items
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
CRMD
FULC
MRNS
9 May 24
with its pioneering targeted radiotherapies.
A Focused Approach on High-Impact Therapies
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14
OCUL
8 May 24
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and lowers the price target from $16 to $14.
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22
OCUL
8 May 24
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and lowers the price target from $24 to $22.
TD Cowen Maintains Hold on Ocular Therapeutix, Lowers Price Target to $7
OCUL
8 May 24
TD Cowen analyst Tara Bancroft maintains Ocular Therapeutix (NASDAQ:OCUL) with a Hold and lowers the price target from $11 to $7.
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
ADCT
BNTX
LAZR
6 May 24
Equal-Weight to Underweight and lowered the price target from $19 to $15.
Now Read
2ip1ab
OCUL
3 May 24
containing the words "anticipate", "believe", "estimate", "expect", "intend", "goal", "may", "might", "plan", "predict", "project", "target", "potential
zc5noh
OCUL
1 May 24
", "expect", "intend", "goal", "may", "might", "plan", "predict", "project", "target", "potential", "will", "would", "could", "should", "continue
oxl7xafrehdv5zxi09xdys5d378hi6kjp r6vkaqp4
OCUL
19 Apr 24
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $16 price target.
8qklg0iy5bq8rmq0y22rnkkg05 3q0
AGBA
ALRN
APOG
18 Apr 24
Thalmann analyst Aydin Huseynov maintained Aileron Therapeutics with a Buy and raised the price target from $9 to $19.
MicroCloud
9bj8ziti
OCUL
18 Apr 24
axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet AMD, DR
7xjg1wp5vs3qst243395z9jijcc0rdaqylfzy9t9r
OCUL
16 Apr 24
0
Analysts have recently evaluated Ocular Therapeutix and provided 12-month price targets. The average
9ok746qa 5p75tpa7ltz
OCUL
16 Apr 24
JMP Securities analyst Jonathan Wolleben reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and maintains $24 price target.
6yqz8cb
OCUL
16 Apr 24
", "might", "plan", "predict", "project", "target", "potential", "will", "would", "could", "should", "continue
5by748zv3xa50nsreu7zbbne2qxjd99hfp9adj2i5v
OCUL
6 Apr 24
", "estimate", "expect", "intend", "goal", "may", "might", "plan", "predict", "project", "target
7h0pb1h4h8jyaon4xdbd5eduuek874
OCUL
13 Mar 24
JMP Securities analyst Jonathan Wolleben reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and maintains $24 price target.
9hqtgjsv4c
OCUL
13 Mar 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing
b9fq pdh5svyuk4i6pskg7e297fsjx26dq8740vgh
OCUL
13 Mar 24
HC Wainwright & Co. analyst Yi Chen maintains Ocular Therapeutix (NASDAQ:OCUL) with a Buy and raises the price target from $12 to $15.
- Prev
- 1
- Next